The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial. METHODS: We randomly assigned adults (18 to 59 years of age) with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without rituximab, with event-free survival as the primary end point. Rituximab was given during all treatment phases, for a total of 16 to 18 infusions. RESULTS: From May 2006 through April 2014, a total of 209 patients were enrolled: 105 in the rituximab group and 104 in the control group. After a median follow-up of 30 months, event-free survival was longer in the rituximab group than in the control group (hazard ratio, 0.66; 95% confidence interval [CI], 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95% CI, 43 to 63), respectively. Treatment with rituximab remained associated with longer event-free survival in a multivariate analysis. The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. CONCLUSIONS: Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Self-citationMoorman, A. V., Harrison, C. J., Buck, G. A. N., Richards, S. M., Secker-Walker, L. M., Martineau, M., Vance, G. H., Cherry, A. M., Higgins, R. R., Fielding, A. K., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051912 · Cited by 753
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 567
Self-citationAvramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Beldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M.-L., Leguay, T., Thomas, X., Cayuela, J.-M., Grardel, N., Chalandon, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547695 · Cited by 330
Self-citationKantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., et al. (2013) · Cancer · doi:10.1002/cncr.28136 · Cited by 306
Hoelzer, D., Walewski, J., Döhner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Dührsen, U., Hüttmann, A., Thiel, E., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563627 · Cited by 289
Dhédin, N., Huynh, A., Maury, S., Tabrizi, R., Beldjord, K., Asnafi, V., Thomas, X., Chevallier, P., Nguyen, S., Coiteux, V., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599894 · Cited by 270
Self-citationRibrag, V., Koscielny, S., Bosq, J., Leguay, T., Casasnovas, O., Fornecker, L.-M., Recher, C., Ghesquieres, H., Morschhauser, F., Girault, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01317-3 · Cited by 185
Self-citationWoo, M. H., Hak, L. J., Storm, M. C., Sandlund, J. T., Ribeiro, R. C., Rivera, G. K., Rubnitz, J. E., Harrison, P. L., Wang, B., Evans, W. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1525 · Cited by 182
Chemoimmunotherapy in acute lymphoblastic leukemia
Hoelzer, D. F., & Gökbuget, N. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.08.001 · Cited by 98
Multinomial regression models based on continuation ratios
Cox, C. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070309 · Cited by 72
T-cell adoptive immunotherapy for acute lymphoblastic leukemia
Fry, T. J., & Mackall, C. L. (2013) · Hematology · doi:10.1182/asheducation-2013.1.348 · Cited by 41
Pediatric-Like Therapy for Adults with ALL
Dombret, H., Cluzeau, T., Huguet, F., & Boissel, N. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0210-9 · Cited by 40
Self-citationThe use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia
DeAngelo, D. J. (2015) · Hematology · doi:10.1182/asheducation-2015.1.400 · Cited by 21
Cited by
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationMalard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 488
Metadata
- Authors
- Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., Chevallier, P., Hunault, M., Boissel, N., Escoffre-Barbe, M., Hess, U., Vey, N., Pignon, J.-M., Braun, T., Marolleau, J.-P., Cahn, J.-Y., Chalandon, Y., Lhéritier, V., Beldjord, K., Béné, M. C., Ifrah, N., & Dombret, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09-15
- Volume
- 375
- Issue
- 11
- Pages
- 1044-1053
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2520695016
- Cited by
- 353
- References
- 22
- FWCI
- 40.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.